Journal of Cutaneous Medicine and Surgery最新文献

英文中文

Oncologic and Surgical Outcomes of Head and Neck Non-Melanoma Skin Cancer: A Systematic Review and Meta-Analysis of Wide Local Excision Versus Mohs Micrographic Surgery. 头颈部非黑色素瘤皮肤癌的肿瘤和手术结果：广泛局部切除与Mohs显微摄影手术的系统回顾和荟萃分析。

IF 3.9 4区医学 Q2 DERMATOLOGY

Journal of Cutaneous Medicine and Surgery

Pub Date : 2026-01-07 DOI: 10.1177/12034754251408396

Houriah Y Nukaly, Abdulaziz M Alghamdi, Abdulaziz G Aljohani, Maan Almaghrabi, Jamal Ali Aljuhani, Mohamed Alqazenli, Suzana Ezzi, Ghassan Barnawi, Talah Alturkistani, Abdulhadi Jfri, Ivan V Litvinov

引用次数: 0

A Pilot Study on the Use of Therapy Dogs to Reduce Anxiety in a Pediatric Alopecia Areata Clinic. 在儿童斑秃诊所使用治疗犬减少焦虑的初步研究。

IF 3.9 4区医学 Q2 DERMATOLOGY

Journal of Cutaneous Medicine and Surgery

Pub Date : 2026-01-07 DOI: 10.1177/12034754251410191

Megan Park, Samiha Mohsen, Cathryn Sibbald

引用次数: 0

A Cross-Sectional Analysis of the Quality and Readability of Online Resources for Alopecia Areata. 斑秃在线资源质量和可读性的横断面分析。

IF 3.9 4区医学 Q2 DERMATOLOGY

Journal of Cutaneous Medicine and Surgery

Pub Date : 2026-01-06 DOI: 10.1177/12034754251410176

Eric McMullen, Grace Xiong, Sana Gupta, Christopher Shenouda, Ashlyn Nguyen, Dea Metko, Shireen Dumont, Ilya Mukovozov, Jeffrey Donovan, Cathryn Sibbald

引用次数: 0

Psychosocial Interventions for Vitiligo: A Scoping Review. 白癜风的社会心理干预：范围综述。

IF 3.9 4区医学 Q2 DERMATOLOGY

Journal of Cutaneous Medicine and Surgery

Pub Date : 2026-01-03 DOI: 10.1177/12034754251409082

Shahnawaz Towheed, Hessa Asmani, Alia Ahmed, Mohammad Jafferany

引用次数: 0

Social Media Response to the Trimethylbenzoyl Diphenylphosphine Oxide Ban in Gel Nail Polish. 社交媒体对凝胶指甲油中禁用三甲基苯甲酰二苯基氧化膦的反应。

IF 3.9 4区医学 Q2 DERMATOLOGY

Journal of Cutaneous Medicine and Surgery

Pub Date : 2025-12-29 DOI: 10.1177/12034754251409048

Natalia V Chalupczak, Shari R Lipner

引用次数: 0

The Characterization of the Relationship Between Field Cancerization and Number of Actinic Keratoses. 野地癌变与光化性角化病数量关系的探讨。

IF 3.9 4区医学 Q2 DERMATOLOGY

Journal of Cutaneous Medicine and Surgery

Pub Date : 2025-12-29 DOI: 10.1177/12034754251408364

Stuti Prajapati, Christina Kontzias, Mallory Zaino, Steven R Feldman

Background: Ultraviolet radiation is responsible for actinic keratoses (AKs) and neoplastic changes surrounding AKs, known as the field of cancerization (FoC). If fields are not appropriately identified and treated, patients remain at risk for developing precancerous lesions and malignant transformation.

Objective: To assess the relationship between FoC and the number of AKs.

Methods: A cross-sectional study was performed on patients with AKs and FoC. Fields were measured, and field characteristics were recorded.

Results: One hundred patients (mean age 71.2 years; 23% female) with 148 FoC participated. Fields were dry (96%), depigmented (79%), and scaly (88%). Mean number of AKs per field was 6.8 [standard deviation (SD) = 7.3]. Mean FoC size was 75.3 cm² (SD = 75 cm²). One hundred and eleven (75%) of the 148 fields exceeded the Food and Drug Administration recommendations for AK field treatment (≤25 cm²). Number of AKs positively correlated with FoC size (P < .0001). Mean FoC size and the mean number of AKs differed among Investigator Global Assessment (IGA) grades (1-3; P = .0396 and P = .0254, respectively). IGA grade positively correlated with FoC size (P = .0041) and average number of AKs (P = .0022).

Conclusion: When selecting AK therapy, dermatologists may consider FoC size, number of AKs, location, IGA grade, and individual risk factors.

背景：紫外线辐射是光化性角化病（AKs）和AKs周围的肿瘤改变的原因，称为癌变场（FoC）。如果没有适当的识别和治疗，患者仍然有发生癌前病变和恶性转化的风险。目的：探讨FoC与ak数量的关系。方法：对AKs和FoC患者进行横断面研究。测量场强，记录场强特征。结果：100例患者（平均年龄71.2岁，女性23%）148例FoC。田地干燥（96%），脱色（79%），鳞片（88%）。每片田平均ak数为6.8只[标准差(SD) = 7.3]。平均FoC大小为75.3 cm2 （SD = 75 cm2）。148个农田中有111个（75%）超过了食品和药物管理局推荐的AK田间处理（≤25 cm2）。ak数量与FoC大小呈正相关(P P =。0396和P =。0254年,分别)。IGA分级与FoC大小（P = 0.0041）、ak平均数目（P = 0.0022）呈正相关。结论：皮肤科医生在选择AK治疗时，可考虑FoC大小、AK数量、位置、IGA等级和个体危险因素。

{"title":"The Characterization of the Relationship Between Field Cancerization and Number of Actinic Keratoses.","authors":"Stuti Prajapati, Christina Kontzias, Mallory Zaino, Steven R Feldman","doi":"10.1177/12034754251408364","DOIUrl":"https://doi.org/10.1177/12034754251408364","url":null,"abstract":"Background: Ultraviolet radiation is responsible for actinic keratoses (AKs) and neoplastic changes surrounding AKs, known as the field of cancerization (FoC). If fields are not appropriately identified and treated, patients remain at risk for developing precancerous lesions and malignant transformation.Objective: To assess the relationship between FoC and the number of AKs.Methods: A cross-sectional study was performed on patients with AKs and FoC. Fields were measured, and field characteristics were recorded.Results: One hundred patients (mean age 71.2 years; 23% female) with 148 FoC participated. Fields were dry (96%), depigmented (79%), and scaly (88%). Mean number of AKs per field was 6.8 [standard deviation (SD) = 7.3]. Mean FoC size was 75.3 cm2 (SD = 75 cm2). One hundred and eleven (75%) of the 148 fields exceeded the Food and Drug Administration recommendations for AK field treatment (≤25 cm2). Number of AKs positively correlated with FoC size (P < .0001). Mean FoC size and the mean number of AKs differed among Investigator Global Assessment (IGA) grades (1-3; P = .0396 and P = .0254, respectively). IGA grade positively correlated with FoC size (P = .0041) and average number of AKs (P = .0022).Conclusion: When selecting AK therapy, dermatologists may consider FoC size, number of AKs, location, IGA grade, and individual risk factors.","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251408364"},"PeriodicalIF":3.9,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145850266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Treatments for Postherpetic Itch: A Systematic Review. 疱疹后瘙痒治疗的有效性和安全性：一项系统综述。

IF 3.9 4区医学 Q2 DERMATOLOGY

Journal of Cutaneous Medicine and Surgery

Pub Date : 2025-12-29 DOI: 10.1177/12034754251409072

Jia Qi Adam Bai, Ryan S Q Geng, Kyobin Hwang, Ilya Mukovozov

引用次数: 0

Association Between Inflammatory Comorbidities and Hidradenitis Suppurativa Disease Characteristics: A Systematic Review and Meta-Analysis. 炎症合并症与化脓性汗腺炎疾病特征之间的关系：系统综述和荟萃分析。

IF 3.9 4区医学 Q2 DERMATOLOGY

Journal of Cutaneous Medicine and Surgery

Pub Date : 2025-12-29 DOI: 10.1177/12034754251408405

Grace Xiong, Laurence Mainville, Raed Alhusayen, Sana Gupta, Shanti Mehta, Wei Wu, Eric McMullen, Fangyi Xie, David Croitoru

引用次数: 0

Streamlining Pediatric Atopic Dermatitis Care Across Inuit Nunangat: Cost Savings and In-Community IL-4/IL-13 Biologic Treatment Initiation. 精简因纽特人努南加特儿童特应性皮炎护理：成本节约和社区内IL-4/IL-13生物治疗启动

IF 3.9 4区医学 Q2 DERMATOLOGY

Journal of Cutaneous Medicine and Surgery

Pub Date : 2025-12-29 DOI: 10.1177/12034754251408404

Meghan Kanou, Sabrina Hundal, Naomy Leclerc, Johnny Hanna, Annie Kumarluk, Nathalie Boulanger, Elena Netchiporouk, Richard Chamberland, Justin Grenier, Ivan V Litvinov

引用次数: 0

Intramuscular Triamcinolone Acetonide Versus Oral Minipulse Dexamethasone in Active Vitiligo: An Observational Study. 肌注曲安奈德与口服小脉冲地塞米松治疗活动性白癜风：一项观察性研究。

IF 3.9 4区医学 Q2 DERMATOLOGY

Journal of Cutaneous Medicine and Surgery

Pub Date : 2025-12-29 DOI: 10.1177/12034754251408391

Chayada Chaiyabutr, Tada Kunavisarut, Teerapat Wannawittayapa, Chutipon Pruksaeakanan, Chanisada Wongpraparut, Narumol Silpa-Archa

Background: Systemic corticosteroids, particularly oral minipulse dexamethasone (OMP-D), are commonly used to stabilize active vitiligo. Intramuscular triamcinolone acetonide (IMTA), though effective in other dermatoses, has limited studies for vitiligo.

Objectives: To compare the efficacy and safety of IMTA versus OMP-D in adults with active vitiligo.

Methods: This observational study included patients aged 18 to 60 years with clinically active vitiligo. Patients received either IMTA 40 mg monthly or OMP-D 2.5 mg twice weekly for 3 months. Vitiligo extent score (VES) and adverse events were assessed at baseline, months 1, 2, 3, and 6. Biochemical parameters were evaluated at baseline and month 3.

Results: Nineteen patients (9 in the IMTA group and 10 in the OMP-D group) were included. All patients achieved disease stabilization within the first month. The IMTA group showed an earlier onset of repigmentation, evidenced by a significant reduction in VES at month 1. By months 2, 3, and 6, both groups demonstrated significant reductions in VES compared to baseline. Notably, at months 2 and 3, the OMP-D group exhibited a more pronounced decrease in VES (P ≤ .01) than the IMTA group (P ≤ .05). One patient in the IMTA group began to experience vitiligo relapse at month 6. Both treatments were well-tolerated. Cortisol suppression was observed in 1 patient from each group.

Conclusions: IMTA shows promising results, comparable in efficacy and safety to OMP-D for active vitiligo, achieving early disease stabilization and repigmentation. IMTA represents a practical first-line alternative for active vitiligo management.

背景：全身皮质类固醇，特别是口服小脉冲地塞米松（OMP-D），常用于稳定活动性白癜风。肌注曲安奈德（IMTA）虽然对其他皮肤病有效，但对白癜风的研究有限。目的：比较IMTA与OMP-D治疗成人活动性白癜风的疗效和安全性。方法：本观察性研究纳入18 ~ 60岁临床活动性白癜风患者。患者接受IMTA每月40毫克或OMP-D 2.5毫克，每周两次，持续3个月。在基线、第1、2、3和6个月评估白癜风程度评分（VES）和不良事件。在基线和第3个月评估生化参数。结果：共纳入19例患者（IMTA组9例，OMP-D组10例）。所有患者均在第一个月内病情稳定。IMTA组出现较早的色素沉着，第1个月时VES显著降低。在第2、3、6个月时，两组患者的VES均显著降低。值得注意的是，在第2个月和第3个月，OMP-D组比IMTA组表现出更明显的VES下降（P≤0.01）。IMTA组中有一名患者在第6个月开始经历白癜风复发。两种治疗方法均耐受良好。两组均有1例患者出现皮质醇抑制。结论：IMTA治疗活动性白癜风的疗效和安全性与OMP-D相当，可实现疾病的早期稳定和再色素沉着。IMTA代表了主动白癜风管理的实际一线替代方案。

{"title":"Intramuscular Triamcinolone Acetonide Versus Oral Minipulse Dexamethasone in Active Vitiligo: An Observational Study.","authors":"Chayada Chaiyabutr, Tada Kunavisarut, Teerapat Wannawittayapa, Chutipon Pruksaeakanan, Chanisada Wongpraparut, Narumol Silpa-Archa","doi":"10.1177/12034754251408391","DOIUrl":"https://doi.org/10.1177/12034754251408391","url":null,"abstract":"Background: Systemic corticosteroids, particularly oral minipulse dexamethasone (OMP-D), are commonly used to stabilize active vitiligo. Intramuscular triamcinolone acetonide (IMTA), though effective in other dermatoses, has limited studies for vitiligo.Objectives: To compare the efficacy and safety of IMTA versus OMP-D in adults with active vitiligo.Methods: This observational study included patients aged 18 to 60 years with clinically active vitiligo. Patients received either IMTA 40 mg monthly or OMP-D 2.5 mg twice weekly for 3 months. Vitiligo extent score (VES) and adverse events were assessed at baseline, months 1, 2, 3, and 6. Biochemical parameters were evaluated at baseline and month 3.Results: Nineteen patients (9 in the IMTA group and 10 in the OMP-D group) were included. All patients achieved disease stabilization within the first month. The IMTA group showed an earlier onset of repigmentation, evidenced by a significant reduction in VES at month 1. By months 2, 3, and 6, both groups demonstrated significant reductions in VES compared to baseline. Notably, at months 2 and 3, the OMP-D group exhibited a more pronounced decrease in VES (P ≤ .01) than the IMTA group (P ≤ .05). One patient in the IMTA group began to experience vitiligo relapse at month 6. Both treatments were well-tolerated. Cortisol suppression was observed in 1 patient from each group.Conclusions: IMTA shows promising results, comparable in efficacy and safety to OMP-D for active vitiligo, achieving early disease stabilization and repigmentation. IMTA represents a practical first-line alternative for active vitiligo management.","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251408391"},"PeriodicalIF":3.9,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145850137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Cutaneous Medicine and Surgery

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀